Swiss National Bank Purchases 700 Shares of LivaNova PLC (NASDAQ:LIVN)

Swiss National Bank grew its position in LivaNova PLC (NASDAQ:LIVN) by 0.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 106,819 shares of the company’s stock after buying an additional 700 shares during the quarter. Swiss National Bank’s holdings in LivaNova were worth $4,947,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Central Pacific Bank Trust Division grew its holdings in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Amalgamated Bank boosted its holdings in LivaNova by 3.0% in the fourth quarter. Amalgamated Bank now owns 24,900 shares of the company’s stock valued at $1,153,000 after acquiring an additional 729 shares during the last quarter. Rhumbline Advisers lifted its position in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after purchasing an additional 899 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after purchasing an additional 1,424 shares during the last quarter. Finally, Diversified Trust Co raised its stake in shares of LivaNova by 9.5% during the fourth quarter. Diversified Trust Co now owns 16,432 shares of the company’s stock worth $761,000 after buying an additional 1,425 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Trading Up 2.3 %

LIVN opened at $40.37 on Tuesday. The stock has a market capitalization of $2.19 billion, a P/E ratio of 96.12 and a beta of 1.10. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12 month low of $36.85 and a 12 month high of $64.48. The firm’s fifty day simple moving average is $45.17 and its 200 day simple moving average is $48.70.

Analysts Set New Price Targets

LIVN has been the subject of several recent research reports. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group lowered their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Barclays reduced their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.